KALV
KalVista Pharmaceuticals, Inc.$16.98+0.61 (+3.71%)Prev Close$16.43·MCap$888.7M·P/E—·Vol790.7K·Yield—
▲
Buys (12M)
1
$235.5K
▼
Sells (12M)
42
$3.69M
◆
Net Activity
Net Seller
$3.46M
●
Active Insiders
6
last 12 mo
Over the past 12 months, insider activity at KalVista Pharmaceuticals, Inc. (KALV) has been dominated by selling, with 1 insider purchase totaling $235.5K and 42 insider sales totaling $3.69M. The most recent insider transaction was by Palleiko Benjamin L (director, officer: CHIEF EXECUTIVE OFFICER), who sold $107.6K worth of shares on Mar 10, 2026. KalVista Pharmaceuticals, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $888.7M.
KALV Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 10, 2026 | Palleiko Benjamin L | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 6,693 | $16.08 | $107.6K | 451,815 |
| Feb 24, 2026 | Audhya Paul K. | officer: CHIEF MEDICAL OFFICER | Sell | 10,708 | $15.57 | $166.7K | 138,983 |
| Feb 24, 2026 | Palleiko Benjamin L | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 20,068 | $15.57 | $312.4K | 442,883 |
| Feb 24, 2026 | Piekos Brian | officer: Chief Financial Officer | Sell | 3,534 | $15.57 | $55.0K | 13,762 |
| Feb 24, 2026 | Sweeny Nicole | officer: Chief Commercial Officer | Sell | 7,950 | $15.57 | $123.8K | 47,003 |
| Feb 24, 2026 | Yea Christopher | officer: CHIEF DEVELOPMENT OFFICER | Sell | 8,694 | $15.57 | $135.3K | 226,701 |
| Feb 17, 2026 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 1,163 | $15.00 | $17.4K | 0 |
| Feb 17, 2026 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 1,038 | $15.00 | $15.6K | 0 |
| Feb 17, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 1,109 | $15.00 | $16.6K | 0 |
| Feb 13, 2026 | Palleiko Benjamin L | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 3,354 | $15.70 | $52.7K | 428,286 |
| Dec 9, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 7,294 | $16.51 | $120.4K | 424,520 |
| Dec 4, 2025 | Sweeny Nicole | Chief Commercial Officer | Sell | 3,813 | $13.45 | $51.3K | 39,728 |
| Nov 26, 2025 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 5,296 | $13.45 | $71.2K | 131,831 |
| Nov 26, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 10,940 | $13.45 | $147.2K | 416,189 |
| Nov 26, 2025 | Piekos Brian | Chief Financial Officer | Sell | 4,471 | $13.45 | $60.1K | 10,529 |
| Nov 26, 2025 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 4,331 | $13.45 | $58.3K | 223,508 |
| Nov 19, 2025 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 3,075 | $14.48 | $44.5K | 125,877 |
| Nov 19, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 4,466 | $14.48 | $64.7K | 403,879 |
| Nov 19, 2025 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 2,683 | $14.48 | $38.8K | 133,574 |
| Nov 13, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 3,328 | $11.55 | $38.4K | 398,981 |
| Sep 9, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 7,294 | $15.84 | $115.5K | 395,189 |
| Aug 26, 2025 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 2,336 | $13.42 | $31.3K | 122,505 |
| Aug 26, 2025 | Sweeny Nicole | Chief Commercial Officer | Sell | 1,480 | $13.42 | $19.9K | 32,291 |
| Aug 26, 2025 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 1,954 | $13.42 | $26.2K | 132,052 |
| Aug 25, 2025 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 2,942 | $13.22 | $38.9K | 119,841 |
| Aug 25, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 10,940 | $13.22 | $144.7K | 386,858 |
| Aug 25, 2025 | Sweeny Nicole | Chief Commercial Officer | Sell | 1,864 | $13.22 | $24.6K | 28,771 |
| Aug 25, 2025 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 2,362 | $13.22 | $31.2K | 130,881 |
| Aug 19, 2025 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 2,939 | $13.19 | $38.8K | 116,533 |
| Aug 19, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 4,409 | $13.19 | $58.1K | 374,548 |
| Aug 19, 2025 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 2,649 | $13.19 | $34.9K | 129,493 |
| Jul 10, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 32,979 | $15.69 | $517.5K | 369,595 |
| Jul 10, 2025 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 30,250 | $15.69 | $474.7K | 127,939 |
| Jun 10, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 7,169 | $14.50 | $104.0K | 315,074 |
| May 27, 2025 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 2,146 | $11.31 | $24.3K | 113,026 |
| May 27, 2025 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 1,926 | $11.31 | $21.8K | 98,189 |
| May 23, 2025 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 2,689 | $11.88 | $31.9K | 110,172 |
| May 23, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 9,999 | $11.88 | $118.7K | 306,618 |
| May 23, 2025 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 2,317 | $11.88 | $27.5K | 96,990 |
| May 20, 2025 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 2,776 | $11.84 | $32.9K | 106,611 |
| May 20, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 3,808 | $11.84 | $45.1K | 293,367 |
| May 20, 2025 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 2,600 | $11.84 | $30.8K | 95,557 |
| Apr 11, 2025 | Venrock Healthcare Capital Partners III, L.P. | Buy | 25,000 | $9.42 | $235.5K | 5,303,985 | |
| Mar 10, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 6,669 | $11.97 | $79.8K | 287,811 |
| Feb 25, 2025 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 2,394 | $10.02 | $24.0K | 102,940 |
| Feb 25, 2025 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 1,918 | $10.02 | $19.2K | 93,952 |
| Feb 19, 2025 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 3,125 | $9.82 | $30.7K | 100,334 |
| Feb 19, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 5,104 | $9.82 | $50.1K | 278,855 |
| Feb 19, 2025 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 2,601 | $9.82 | $25.6K | 92,745 |
| Feb 14, 2025 | Venrock Healthcare Capital Partners III, L.P. | Buy | 161,700 | $9.27 | $1.50M | 5,278,985 |
Showing 1–50 of 139
1 / 3
KALV Insider Buying Activity
The following table shows recent insider purchases of KalVista Pharmaceuticals, Inc. (KALV) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Apr 11, 2025 | Venrock Healthcare Capital Partners III, L.P. | Buy | 25,000 | $9.42 | $235.5K | 5,303,985 | |
| Feb 14, 2025 | Venrock Healthcare Capital Partners III, L.P. | Buy | 161,700 | $9.27 | $1.50M | 5,278,985 |
KALV Insider Selling Activity
The following table shows recent insider sales of KalVista Pharmaceuticals, Inc. (KALV) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 10, 2026 | Palleiko Benjamin L | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 6,693 | $16.08 | $107.6K | 451,815 |
| Feb 24, 2026 | Audhya Paul K. | officer: CHIEF MEDICAL OFFICER | Sell | 10,708 | $15.57 | $166.7K | 138,983 |
| Feb 24, 2026 | Palleiko Benjamin L | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 20,068 | $15.57 | $312.4K | 442,883 |
| Feb 24, 2026 | Piekos Brian | officer: Chief Financial Officer | Sell | 3,534 | $15.57 | $55.0K | 13,762 |
| Feb 24, 2026 | Sweeny Nicole | officer: Chief Commercial Officer | Sell | 7,950 | $15.57 | $123.8K | 47,003 |
| Feb 24, 2026 | Yea Christopher | officer: CHIEF DEVELOPMENT OFFICER | Sell | 8,694 | $15.57 | $135.3K | 226,701 |
| Feb 17, 2026 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 1,163 | $15.00 | $17.4K | 0 |
| Feb 17, 2026 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 1,038 | $15.00 | $15.6K | 0 |
| Feb 17, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 1,109 | $15.00 | $16.6K | 0 |
| Feb 13, 2026 | Palleiko Benjamin L | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 3,354 | $15.70 | $52.7K | 428,286 |
| Dec 9, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 7,294 | $16.51 | $120.4K | 424,520 |
| Dec 4, 2025 | Sweeny Nicole | Chief Commercial Officer | Sell | 3,813 | $13.45 | $51.3K | 39,728 |
| Nov 26, 2025 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 5,296 | $13.45 | $71.2K | 131,831 |
| Nov 26, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 10,940 | $13.45 | $147.2K | 416,189 |
| Nov 26, 2025 | Piekos Brian | Chief Financial Officer | Sell | 4,471 | $13.45 | $60.1K | 10,529 |
| Nov 26, 2025 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 4,331 | $13.45 | $58.3K | 223,508 |
| Nov 19, 2025 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 3,075 | $14.48 | $44.5K | 125,877 |
| Nov 19, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 4,466 | $14.48 | $64.7K | 403,879 |
| Nov 19, 2025 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 2,683 | $14.48 | $38.8K | 133,574 |
| Nov 13, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 3,328 | $11.55 | $38.4K | 398,981 |
| Sep 9, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 7,294 | $15.84 | $115.5K | 395,189 |
| Aug 26, 2025 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 2,336 | $13.42 | $31.3K | 122,505 |
| Aug 26, 2025 | Sweeny Nicole | Chief Commercial Officer | Sell | 1,480 | $13.42 | $19.9K | 32,291 |
| Aug 26, 2025 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 1,954 | $13.42 | $26.2K | 132,052 |
| Aug 25, 2025 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 2,942 | $13.22 | $38.9K | 119,841 |
| Aug 25, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 10,940 | $13.22 | $144.7K | 386,858 |
| Aug 25, 2025 | Sweeny Nicole | Chief Commercial Officer | Sell | 1,864 | $13.22 | $24.6K | 28,771 |
| Aug 25, 2025 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 2,362 | $13.22 | $31.2K | 130,881 |
| Aug 19, 2025 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 2,939 | $13.19 | $38.8K | 116,533 |
| Aug 19, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 4,409 | $13.19 | $58.1K | 374,548 |
| Aug 19, 2025 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 2,649 | $13.19 | $34.9K | 129,493 |
| Jul 10, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 32,979 | $15.69 | $517.5K | 369,595 |
| Jul 10, 2025 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 30,250 | $15.69 | $474.7K | 127,939 |
| Jun 10, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 7,169 | $14.50 | $104.0K | 315,074 |
| May 27, 2025 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 2,146 | $11.31 | $24.3K | 113,026 |
| May 27, 2025 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 1,926 | $11.31 | $21.8K | 98,189 |
| May 23, 2025 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 2,689 | $11.88 | $31.9K | 110,172 |
| May 23, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 9,999 | $11.88 | $118.7K | 306,618 |
| May 23, 2025 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 2,317 | $11.88 | $27.5K | 96,990 |
| May 20, 2025 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 2,776 | $11.84 | $32.9K | 106,611 |
| May 20, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 3,808 | $11.84 | $45.1K | 293,367 |
| May 20, 2025 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 2,600 | $11.84 | $30.8K | 95,557 |
| Mar 10, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 6,669 | $11.97 | $79.8K | 287,811 |
| Feb 25, 2025 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 2,394 | $10.02 | $24.0K | 102,940 |
| Feb 25, 2025 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 1,918 | $10.02 | $19.2K | 93,952 |
| Feb 19, 2025 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 3,125 | $9.82 | $30.7K | 100,334 |
| Feb 19, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 5,104 | $9.82 | $50.1K | 278,855 |
| Feb 19, 2025 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 2,601 | $9.82 | $25.6K | 92,745 |
KALV Insiders
Similar Stocks to KALV
VRTX
Vertex Pharmaceuticals Incorporated
$454.00-0.96%
$115.32B
REGN
Regeneron Pharmaceuticals, Inc.
$732.87-0.89%
$76.15B
ALNY
Alnylam Pharmaceuticals, Inc.
$312.17+0.99%
$41.40B
INSM
Insmed Incorporated
$136.00-4.42%
$29.32B
UTHR
United Therapeutics Corporation
$524.28-0.61%
$23.50B
MRNA
Moderna, Inc.
$50.80-3.04%
$20.76B
ROIV
Roivant Sciences Ltd.
$27.22-2.16%
$20.08B
RPRX
Royalty Pharma plc
$45.37-0.35%
$19.56B